Shares of Adeia Corp. tumbled as much as 17.3% to $22.99 after investors digested the patent-licensing company's second-quarter results and decided a tiny revenue miss mattered more than a bigger long-term vision. The sell-off, which erased a multi-day rally that had pushed the stock from $23.16 to $27.79 in five sessions, exposes a core tension: can a company built on licensing deals convince Wall Street to look past lumpy quarterly numbers?
A Revenue Miss Smaller Than a Rounding Error Spooked the Market
Despite beating earnings expectations with adjusted EPS of $0.34 versus the $0.31 consensus, shares cratered after revenue of $96.1 million came in just $0.69 million below the $96.79 million forecast.
In a licensing business where deal timing can significantly impact quarterly results, that sub-1% shortfall raised questions about the pace of new agreement closings. For a stock that had rallied ~20% in a week, any excuse to take profits was enough.
The Chip Bet Got Bigger — and More Ambitious
Management raised its long-term annual revenue target from $500 million to $600 million, primarily driven by a doubled outlook for the semiconductor business to $200 million annually.
The semiconductor unit posted $14.8 million in Q2 and $48 million year-to-date — already surpassing last year's $26 million full-year total. The growth is real, but the gap between $48 million today and a $200 million target underscores how much execution still needs to go right.
Old-Line Pay-TV Is Shrinking, but Replacement Revenue Is Arriving Fast
Adeia added a record 12 new customers, including a multi-year Google renewal and an e-commerce deal through RPX covering 10 companies. Non-pay-TV recurring revenue grew 54% year-over-year and is now nearly double pay-TV recurring revenue.
Yet the legacy Pay-TV business faces headwinds, including new patent litigation filed against FuboTV after failing to reach a license agreement.
Leadership Void Adds a Wild Card
The CEO search process is ongoing, with a successor not expected until Q4 2026, creating potential leadership uncertainty.
Meanwhile, 2026 revenue guidance stays at $395–$435 million, with deals potentially back-end loaded.
Analysts maintain an average "Moderate Buy" rating with a $33.60 price target — roughly 46% above today's depressed level. The question is whether patient shareholders get rewarded or whether the lumpy reality of licensing keeps punishing the stock quarter after quarter.